226 related articles for article (PubMed ID: 32532990)
21. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication.
Hoopes JI; Cortez LM; Mertz TM; Malc EP; Mieczkowski PA; Roberts SA
Cell Rep; 2016 Feb; 14(6):1273-1282. PubMed ID: 26832400
[TBL] [Abstract][Full Text] [Related]
22. [Expression and activity identification of APOBEC3A-HBc fusion protein].
DU J; Cheng S; Bai H; Ji Q; Guo Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1521-1528. PubMed ID: 29268857
[TBL] [Abstract][Full Text] [Related]
23. An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers.
Chan K; Roberts SA; Klimczak LJ; Sterling JF; Saini N; Malc EP; Kim J; Kwiatkowski DJ; Fargo DC; Mieczkowski PA; Getz G; Gordenin DA
Nat Genet; 2015 Sep; 47(9):1067-72. PubMed ID: 26258849
[TBL] [Abstract][Full Text] [Related]
24. Clinical implications of APOBEC3A and 3B expression in patients with breast cancer.
Kim YS; Sun S; Yoon JS; Ko YH; Won HS; Kim JS
PLoS One; 2020; 15(3):e0230261. PubMed ID: 32176735
[TBL] [Abstract][Full Text] [Related]
25. An extended APOBEC3A mutation signature in cancer.
Langenbucher A; Bowen D; Sakhtemani R; Bournique E; Wise JF; Zou L; Bhagwat AS; Buisson R; Lawrence MS
Nat Commun; 2021 Mar; 12(1):1602. PubMed ID: 33707442
[TBL] [Abstract][Full Text] [Related]
26. Mesoscale DNA features impact APOBEC3A and APOBEC3B deaminase activity and shape tumor mutational landscapes.
Sanchez A; Ortega P; Sakhtemani R; Manjunath L; Oh S; Bournique E; Becker A; Kim K; Durfee C; Temiz NA; Chen XS; Harris RS; Lawrence MS; Buisson R
Nat Commun; 2024 Mar; 15(1):2370. PubMed ID: 38499542
[TBL] [Abstract][Full Text] [Related]
27. A digital PCR-based protocol to detect and quantify RNA editing events at hotspots.
Oh S; Buisson R
STAR Protoc; 2022 Mar; 3(1):101148. PubMed ID: 35284835
[TBL] [Abstract][Full Text] [Related]
28. APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers.
Kondo S; Wakae K; Wakisaka N; Nakanishi Y; Ishikawa K; Komori T; Moriyama-Kita M; Endo K; Murono S; Wang Z; Kitamura K; Nishiyama T; Yamaguchi K; Shigenobu S; Muramatsu M; Yoshizaki T
Oncogene; 2017 Mar; 36(12):1687-1697. PubMed ID: 27694899
[TBL] [Abstract][Full Text] [Related]
29. Improvement of C-to-U RNA editing using an artificial MS2-APOBEC system.
Li J; Fan G; Sakari M; Tsukahara T
Biotechnol J; 2024 Jan; 19(1):e2300321. PubMed ID: 38010373
[TBL] [Abstract][Full Text] [Related]
30. DNA Deamination Is Required for Human APOBEC3A-Driven Hepatocellular Carcinoma In Vivo.
Naumann JA; Argyris PP; Carpenter MA; Gupta HB; Chen Y; Temiz NA; Zhou Y; Durfee C; Proehl J; Koniar BL; Conticello SG; Largaespada DA; Brown WL; Aihara H; Vogel RI; Harris RS
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298259
[TBL] [Abstract][Full Text] [Related]
31. Murine leukemia virus resists producer cell APOBEC3A by its Glycosylated Gag but not target cell APOBEC3A.
Jaguva Vasudevan AA; Balakrishnan K; Franken A; Krikoni A; Häussinger D; Luedde T; Münk C
Virology; 2021 May; 557():1-14. PubMed ID: 33581610
[TBL] [Abstract][Full Text] [Related]
32. HMCES Maintains Replication Fork Progression and Prevents Double-Strand Breaks in Response to APOBEC Deamination and Abasic Site Formation.
Mehta KPM; Lovejoy CA; Zhao R; Heintzman DR; Cortez D
Cell Rep; 2020 Jun; 31(9):107705. PubMed ID: 32492421
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo.
Law EK; Levin-Klein R; Jarvis MC; Kim H; Argyris PP; Carpenter MA; Starrett GJ; Temiz NA; Larson LK; Durfee C; Burns MB; Vogel RI; Stavrou S; Aguilera AN; Wagner S; Largaespada DA; Starr TK; Ross SR; Harris RS
J Exp Med; 2020 Dec; 217(12):. PubMed ID: 32870257
[TBL] [Abstract][Full Text] [Related]
34. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death.
Mussil B; Suspène R; Aynaud MM; Gauvrit A; Vartanian JP; Wain-Hobson S
PLoS One; 2013; 8(8):e73641. PubMed ID: 23977391
[TBL] [Abstract][Full Text] [Related]
35. Passenger hotspot mutations in cancer driven by APOBEC3A and mesoscale genomic features.
Buisson R; Langenbucher A; Bowen D; Kwan EE; Benes CH; Zou L; Lawrence MS
Science; 2019 Jun; 364(6447):. PubMed ID: 31249028
[TBL] [Abstract][Full Text] [Related]
36. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism.
Chen TW; Lee CC; Liu H; Wu CS; Pickering CR; Huang PJ; Wang J; Chang IY; Yeh YM; Chen CD; Li HP; Luo JD; Tan BC; Chan TEH; Hsueh C; Chu LJ; Chen YT; Zhang B; Yang CY; Wu CC; Hsu CW; See LC; Tang P; Yu JS; Liao WC; Chiang WF; Rodriguez H; Myers JN; Chang KP; Chang YS
Nat Commun; 2017 Sep; 8(1):465. PubMed ID: 28878238
[TBL] [Abstract][Full Text] [Related]
37. Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells.
Dennis M; Hurley A; Bray N; Cordero C; Ilagan J; Mertz TM; Roberts SA
PLoS Genet; 2024 May; 20(5):e1011293. PubMed ID: 38805570
[TBL] [Abstract][Full Text] [Related]
38. Cytidine deaminase Apobec3a induction in fallopian epithelium after exposure to follicular fluid.
Brachova P; Alvarez NS; Van Voorhis BJ; Christenson LK
Gynecol Oncol; 2017 Jun; 145(3):577-583. PubMed ID: 28215840
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide mapping of regions preferentially targeted by the human DNA-cytosine deaminase APOBEC3A using uracil-DNA pulldown and sequencing.
Sakhtemani R; Senevirathne V; Stewart J; Perera MLW; Pique-Regi R; Lawrence MS; Bhagwat AS
J Biol Chem; 2019 Oct; 294(41):15037-15051. PubMed ID: 31431505
[TBL] [Abstract][Full Text] [Related]
40. Human Tribbles 3 protects nuclear DNA from cytidine deamination by APOBEC3A.
Aynaud MM; Suspène R; Vidalain PO; Mussil B; Guétard D; Tangy F; Wain-Hobson S; Vartanian JP
J Biol Chem; 2012 Nov; 287(46):39182-92. PubMed ID: 22977230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
